NCT06022419 Conservative Therapy of Proximal Phalanx Fractures - Comparing the Lucerne Cast With Finger Splinting
| NCT ID | NCT06022419 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Proximal Phalanx Fracture |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 86 participants in total. It began in 2023-10-01 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this prospective randomized controlled clinical trial is to evaluate if the lucerne cast leads to a better functional outcome than a forearm cast with a finger splint in patients with a proximal phalanx fracture.
Eligibility Criteria
Inclusion Criteria: * Proximal phalanx fracture in the fingers (II - V) * Patient age between 18 and 70 years Exclusion Criteria: * Condylar fracture * Avulsions of the collateral ligament * Pathologic fracture * Intraarticular fracture * Patients unable to consent * Polytraumatized patients * Patients initially presenting more than 7 days after injury * Pregnancy * Compound fractures * Multiple hand injuries
Contact & Investigator
Gerhild Thalhammer, M.D.
STUDY DIRECTOR
Medical University of Vienna
Frequently Asked Questions
Who can join the NCT06022419 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Proximal Phalanx Fracture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06022419 currently recruiting?
Yes, NCT06022419 is actively recruiting participants. Contact the research team at paul.hoppe@meduniwien.ac.at for enrollment information.
Where is the NCT06022419 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT06022419 clinical trial?
NCT06022419 is sponsored by Medical University of Vienna. The principal investigator is Gerhild Thalhammer, M.D. at Medical University of Vienna. The trial plans to enroll 86 participants.